Comparative study of efficacy and safety of Omnic OCAS and doxazosin
- Authors: Davidov MI1, Davidov MI1
-
Affiliations:
- Issue: No 9 (2009)
- Pages: 76-82
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/277094
- ID: 277094
Cite item
Full Text
Abstract
It includes the results of the comparison study of efficiency and safety of Omnic Okas (tamsulosin) and doxazosin in the treatment of benign prostatic hyperplasia (BPH). The open 12-weeks trial included 62 patients with BPH. The positive results of Omnic Okas treatment were achieved in 96,7% of patients. The symptom index IPSS decreased on 53%, nocturia in 4,9 times, quality of life increased in 2,1 times, maximal urinary flow rate - on 55%, the residual urine decreased on 70%, adverse effects revealed in 3,3% patients. Positive effect was achieved in 71,9% and safety in 75,0%. Doxazosin have no advantages compared with Omnic Okas. The frequency of adverse effects was in 3,1-18,8%. Doxazosin decreased systolic and diastolic blood pressure on 19 and 9 hg mm, myocardial ischemia - in 15,6%, and arrhythmias - in 12,5% patients, positive orthostatic test was registered in 37,5% of patients. Omnic Okas was more effective and safe drug for treating symptoms of BPH.
References
- Лопаткин Н.А. Доброкачественная гиперплазия предстательной железы. М., 1999. 216 с.
- Урология по Дональду Смиту / Под ред. Э. Танахо, Дж. Маканинча. Пер. с англ. М., 2005. 819 с.
- Рациональная фармакотерапия в урологии / Под ред. Н.А. Лопаткина, Т.С. Перепановой. М., 2006. С. 258-290.
- Abrams P, Schulman CC, Vaage S, et al. Tamsulosin Study Group: Tamsulosin, a selective als-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic obstruction. Br J Urol 1995;76:325-26.
- Chapple CR, Wyndaele JJ, Nordling J, et al. Tamsulosin, the first prostate-selective a1A-adrenoceptor antagonist: a metaanalysis of two randomized, placebo-controlled multi-centre studies in patients with begign prostatic obstruction. Eur Urol 1996;29:155-67.
- Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998;51:892-900.
- Лопаткин Н.А., Пытель Ю.А., Трапезникова М.Ф. и др. Омник (тамсулозин) в лечении больных с доброкачественной гиперплазией предстательной железы // Урология. 2001. № 1. С. 3-10.
- Djavan B. Lower urinary tract symptoms/benign prostatic hyperplasia: fast control of the patients quality of life. Urology 2003;62(3):6-14.
- Hofner K, Claes H, De Reijke TM, et al. Tamsulosin 0,4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:335-41.
- Лопаткин Н.А., Аляев Ю.Г., Коган М.И. и др. Эффективность и безопасность применения доксазозина (кардуры) при лечении больных с доброкачественной гиперплазией предстательной железы // Урология. 2003. № 5. С. 3-4.
- Мазо Е.Б., Чепуров А.К. Тонокардин (доксазозин) в лечении симптомов нижних мочевых путей // Урология. 2003. № 3. С. 15-16.
- Chapple CR. Eur Urol 2005;4(2):33-34.
- Djavan B. Eur Urol 2005;4(2):61-68.
- Michel MC. Eur Urol 2005;4(2):53-60.
- Савенков М.П., Иванов С.Н., Судакова Н.И. и др. Применение альфа-адреноблокаторов при доброкачественной гиперплазии предстательной железы: есть ли повод для сотрудничества с кардиологом? // Фарматека. 2004. № 16. С. 2-8.
- Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36(1):1-13.
- Foglar R, Shibata K, Horia K, et al. Use of recombinant 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 1995;288:201-07.
- Pressel S, Davis B, Wright J. Operational aspects of terminating the doxazosin arm of the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). Controlled Clin Trials 2001;22:29-41.
Supplementary files
